Daiichi Sankyo Company Performance dei guadagni passati

Il passato criteri di controllo 5/6

Daiichi Sankyo Company ha registrato una crescita degli utili a un tasso medio annuo di 15.9%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 4.3%. I ricavi sono stati in crescita a un tasso medio annuo di 13%. Il ritorno sul capitale proprio di Daiichi Sankyo Company è 15.4% e ha margini netti di 14.2%.

Informazioni chiave

15.9%

Tasso di crescita degli utili

16.3%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	3.4%
Tasso di crescita dei ricavi	13.0%
Rendimento del capitale proprio	15.4%
Margine netto	14.2%
Prossimo aggiornamento sui guadagni	31 Jan 2025

Aggiornamenti sulle prestazioni recenti

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Nov 07

Recent updates

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Nov 07

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Nov 04

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Sep 22

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Sep 06

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 03

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26

Ripartizione dei ricavi e delle spese

Come Daiichi Sankyo Company guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

TSE:4568 Ricavi, spese e utili (JPY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	1,758,071	250,400	696,740	392,404
30 Jun 24	1,687,028	229,101	675,532	388,731
31 Mar 24	1,601,688	200,731	636,997	365,169
31 Dec 23	1,503,471	186,052	578,348	358,217
30 Sep 23	1,397,025	147,885	538,976	357,008
30 Jun 23	1,348,996	147,350	511,428	343,791
31 Mar 23	1,278,478	109,188	471,221	341,570
31 Dec 22	1,182,201	59,354	435,551	331,522
30 Sep 22	1,122,724	62,816	404,552	301,836
30 Jun 22	1,061,140	50,603	375,565	281,129
31 Mar 22	1,044,892	66,972	358,309	260,228
31 Dec 21	1,034,692	94,470	357,377	232,834
30 Sep 21	1,012,313	86,756	348,080	231,885
30 Jun 21	989,638	79,321	340,406	232,560
31 Mar 21	962,516	75,958	333,079	227,353
31 Dec 20	963,552	70,599	323,363	224,168
30 Sep 20	982,388	116,315	320,481	216,129
30 Jun 20	969,501	117,584	310,949	205,104
31 Mar 20	981,793	129,074	302,320	197,465
31 Dec 19	983,669	148,891	287,414	198,066
30 Sep 19	962,440	113,821	279,588	195,904
30 Jun 19	953,219	112,805	275,245	199,435
31 Mar 19	929,717	93,409	277,695	203,711
31 Dec 18	922,228	66,479	283,615	203,000
30 Sep 18	937,648	70,018	290,411	206,117
30 Jun 18	946,829	55,081	296,677	233,531
31 Mar 18	960,195	60,282	301,845	236,046
31 Dec 17	961,766	37,887	298,758	246,479
30 Sep 17	966,509	38,758	300,781	242,153
30 Jun 17	953,255	52,017	303,760	215,721
31 Mar 17	955,124	53,466	302,475	214,347
31 Dec 16	962,296	59,736	316,918	214,027
30 Sep 16	965,681	60,572	325,970	216,074
30 Jun 16	989,001	77,951	326,613	211,564
31 Mar 16	986,446	82,282	328,755	208,656
31 Dec 15	839,759	55,256	269,399	186,615
30 Sep 15	872,744	67,132	284,021	190,206
30 Jun 15	903,340	61,708	306,873	191,180
31 Mar 15	919,372	46,762	331,195	190,666
31 Dec 14	1,149,342	88,276	266,861	333,388
30 Sep 14	1,127,233	80,437	405,500	185,139
30 Jun 14	1,120,177	69,910	361,139	234,391
31 Mar 14	1,118,241	60,943	413,187	191,212
31 Dec 13	1,059,287	90,021	419,188	183,047

Guadagni di qualità: 4568 ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 4568 (14.2%) 4568 sono più alti rispetto allo scorso anno (10.6%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 4568 sono cresciuti del 15.9% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di 4568 nell'ultimo anno ( 69.3% ) supera la media quinquennale ( 15.9% all'anno).

Guadagni vs Settore: La crescita degli utili 4568 nell'ultimo anno ( 69.3% ) ha superato la percentuale del settore Pharmaceuticals 12.2%.

Daiichi Sankyo Company Performance dei guadagni passati

Il passato criteri di controllo 5/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited to Report Q2, 2025 Results on Oct 31, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors

Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO

Daiichi Sankyo Company, Limited to Report Q2, 2025 Results on Oct 31, 2024

IHH Healthcare Berhad Provides Update on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

European Medicines Agency Validates Type II Variation Application for Daiichi Sankyo Company, Limited's ENHERTU

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Final dividend of JP¥30.00 announced

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited to Report Q1, 2025 Results on Jul 31, 2024

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Investor sentiment improves as stock rises 15%

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 27% overvalued after recent price rise

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate